Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:IKTNYSE:PLXNYSE:PRMENASDAQ:PRVL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIKTInhibikase Therapeutics$1.65-1.2%$1.96$1.12▼$4.20$122.66M0.94244,968 shs177,400 shsPLXProtalix BioTherapeutics$1.45+2.8%$1.97$0.82▼$3.10$115.43M-0.2560,434 shs708,182 shsPRMEPrime Medicine$2.65+9.5%$1.54$1.11▼$6.75$347.93M1.551.48 million shs2.65 million shsPRVLPrevail Therapeutics$23.00$23.01$9.02▼$23.35$787.66M1.59955,800 shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIKTInhibikase Therapeutics-1.20%-2.94%-6.78%-27.95%+17.02%PLXProtalix BioTherapeutics+2.84%+3.57%-7.05%-43.80%+17.89%PRMEPrime Medicine+9.50%+47.22%+108.66%+33.17%-47.78%PRVLPrevail Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIKTInhibikase Therapeutics1.4745 of 5 stars3.31.00.00.00.00.01.3PLXProtalix BioTherapeutics2.6711 of 5 stars3.54.00.00.00.60.01.9PRMEPrime Medicine3.907 of 5 stars4.41.00.00.03.45.00.6PRVLPrevail TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIKTInhibikase Therapeutics 2.50Moderate Buy$6.50293.94% UpsidePLXProtalix BioTherapeutics 3.00Buy$15.00934.48% UpsidePRMEPrime Medicine 2.75Moderate Buy$10.08280.50% UpsidePRVLPrevail Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PRVL, PRME, IKT, and PLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025PRMEPrime MedicineCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$10.00 ➝ $1.505/20/2025PRMEPrime MedicineJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.005/20/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/20/2025PRMEPrime MedicineJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral5/19/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.003/28/2025IKTInhibikase TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIKTInhibikase Therapeutics$260K471.79N/AN/A$1.78 per share0.93PLXProtalix BioTherapeutics$59.76M1.93$0.08 per share17.80$0.47 per share3.09PRMEPrime Medicine$3.85M90.47N/AN/A$1.37 per share1.93PRVLPrevail TherapeuticsN/AN/AN/AN/A$4.85 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/APLXProtalix BioTherapeutics$8.31M$0.04N/A4.68N/A-21.03%-30.89%-11.74%N/APRMEPrime Medicine-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/APRVLPrevail Therapeutics-$63.19M-$2.22N/AN/AN/AN/A-55.57%-48.14%N/ALatest PRVL, PRME, IKT, and PLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1PLXProtalix BioTherapeuticsN/A-$0.05N/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIKTInhibikase TherapeuticsN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/APRMEPrime Medicine$1.4554.57%N/AN/A N/APRVLPrevail TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIKTInhibikase TherapeuticsN/A0.850.85PLXProtalix BioTherapeuticsN/A1.981.27PRMEPrime MedicineN/A6.506.50PRVLPrevail TherapeuticsN/A7.567.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIKTInhibikase Therapeutics3.81%PLXProtalix BioTherapeutics16.53%PRMEPrime Medicine70.37%PRVLPrevail Therapeutics86.80%Insider OwnershipCompanyInsider OwnershipIKTInhibikase Therapeutics7.30%PLXProtalix BioTherapeutics6.50%PRMEPrime Medicine22.93%PRVLPrevail Therapeutics57.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionablePLXProtalix BioTherapeutics20079.61 million69.00 millionOptionablePRMEPrime Medicine234131.29 million100.38 millionOptionablePRVLPrevail Therapeutics6634.25 millionN/ANot OptionablePRVL, PRME, IKT, and PLX HeadlinesRecent News About These CompaniesPrevail, Inc. receives $120K grant from Hamilton County Community FoundationMay 29, 2025 | readthereporter.comRI Prevail Announce Split With Co-Vocalist Brian Burkheiser in New StatementMay 16, 2025 | msn.comPrevail Bank donates to 29 charitable programsApril 29, 2025 | wausaupilotandreview.comWLeawood-based Prevail launches $100M VC fund, makes first two investmentsApril 9, 2025 | bizjournals.comData supports Medtronic Prevail paclitaxel-coated balloonMarch 10, 2025 | massdevice.comPrevail Bank’s matching funds campaign garners more than $20KDecember 30, 2024 | wausaupilotandreview.comWPrevail provides holiday hope to 55 families who need it mostDecember 24, 2024 | msn.comPrevail receives $10,000 gift from Elements CaresDecember 11, 2024 | readthereporter.comRI Prevail + Hollywood Undead SCREAM Through Haunted Blood Prison | Paranormal PrisonNovember 13, 2024 | msn.comPrevail Bank launches Holiday Matching Funds campaignNovember 7, 2024 | centralwinews.comCHow I Prevail and All Time Low teamed up to create their monster hit “Hate This Song”November 4, 2024 | yahoo.comPrevail Endowment receives $1M gift honoring Frank Pichler’s LegacyNovember 1, 2024 | readthereporter.comRIllinois Takes on the Ducks: Will Toughness Prevail?October 25, 2024 | msn.comMedtronic’s Prevail DCB pivotal trial receives FDA IDE approvalOctober 25, 2024 | msn.comFDA approves IDE for Medtronic Prevail drug-coated balloonOctober 23, 2024 | massdevice.comPasto Italiano goes Purple for PrevailOctober 21, 2024 | readthereporter.comRSlaughter to Prevail’s Epic New Song ‘Behelit’ Has Fans Reacting to Different StyleOctober 16, 2024 | msn.comInto A Third Future in Sparking Zero, Unlock The Three Prevail PathOctober 14, 2024 | gamepressure.comGLiberty vs. Aces Series Analysis: Who Will Prevail?October 4, 2024 | msn.comComo’s ‘May Peace Prevail on Earth’ building stands tallSeptember 30, 2024 | mndaily.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRVL, PRME, IKT, and PLX Company DescriptionsInhibikase Therapeutics NYSE:IKT$1.65 -0.02 (-1.20%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$1.65 0.00 (0.00%) As of 06/26/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Protalix BioTherapeutics NYSE:PLX$1.45 +0.04 (+2.84%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$1.44 -0.01 (-0.62%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.Prime Medicine NYSE:PRME$2.65 +0.23 (+9.50%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$2.65 0.00 (-0.04%) As of 04:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.Prevail Therapeutics NASDAQ:PRVLPrevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
